Market Place
Sourcing Support
VBI Vaccines Provides an Update on its Restructuring Proceedings
02 Aug 2024 //
BUSINESSWIRE
VBI Vaccines Initiates CCAA Restructuring Proceedings
30 Jul 2024 //
BUSINESSWIRE
VBI Vaccines secures court protection as it restructures, seeks buyer(s)
30 Jul 2024 //
FIERCE BIOTECH
VBI Vaccines Announces AGM Results
25 Jun 2024 //
BUSINESSWIRE
VBI`s VBI-1901 Tumor Response Data In Recurrent Glioblastoma Phase 2b
29 May 2024 //
BUSINESSWIRE
VBI Presents VBI-1901 Interim Glioblastoma Phase 2b At ASCO
22 May 2024 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2024 Financial Results
15 May 2024 //
BUSINESSWIRE
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 2024 //
BUSINESSWIRE
VBI $2M Registered Direct Offering Per Nasdaq
11 Apr 2024 //
BUSINESSWIRE
VBI Vaccines Announces $2M Direct Offering
09 Apr 2024 //
BUSINESSWIRE
VBI Announces Strategic Partnership with Canadian Govt to for Vaccine Platform
02 Apr 2024 //
BUSINESSWIRE
VBI Vaccines shrinks `long-term burn` with $33M Brii Bio deal
14 Feb 2024 //
FIERCE PHARMA
VBI Vaccines Presents Biomarker Data from Phase 1/2a Study of VBI-1901
20 Nov 2023 //
BUSINESSWIRE
VBI Vaccines Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
VBI Vaccines Expands Proprietary Technology Platforms
26 Oct 2023 //
BUSINESSWIRE
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901
27 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901
07 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Partner Brii Announces Results of Phase 2 Study Evaluating BRII-179
06 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option
24 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbri is Available in Netherlands and Belgium
19 Jul 2023 //
PRESS RELEASE
Brii pays VBI $15M for global rights to hepB program and more
06 Jul 2023 //
FIERCE BIOTECH
VBI Vaccines Announces Pricing of $18 Million Public Offering
06 Jul 2023 //
BUSINESSWIRE
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership
05 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces Proposed Concurrent Public Offering of Common Shares
05 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom
15 Jun 2023 //
BUSINESSWIRE
VBI Vaccines Announces Poster Presentation at EASL 2023
07 Jun 2023 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2023 Financial Results
15 May 2023 //
BUSINESSWIRE
VBI Vaccines pares down pipeline, staff to focus on hepatitis B
04 Apr 2023 //
FIERCE BIOTECH
VBI Vaccines Reports Full Year 2022 Financial Results
13 Mar 2023 //
BUSINESSWIRE
VBI to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
23 Feb 2023 //
BUSINESSWIRE
VBI Announces Presentation of PII Evaluating Combination of VBI-2601 & BRII-835
15 Feb 2023 //
BUSINESSWIRE
VBI Vaccines Announces Health Canada Approval for PreHevbrio™
08 Dec 2022 //
BUSINESSWIRE
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901
22 Nov 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual HBV Conference
17 Oct 2022 //
BUSINESSWIRE
VBI & Agenus Collaborates to Evaluate VBI-1901 in with Anti-PD-1 in PII Study
12 Oct 2022 //
BUSINESSWIRE
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent VBI-2901
29 Sep 2022 //
VBIVACCINES
VBI Vaccines Announces Presentation of Data of 3-Antigen Hepatitis B Vaccine
21 Sep 2022 //
BUSINESSWIRE
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
15 Sep 2022 //
BUSINESSWIRE
Valneva & VBI Vaccines Announce European Partnership for Marketing of PreHevbri®
07 Sep 2022 //
GLOBENEWSWIRE
VBI Vaccines Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
12 Jul 2022 //
BUSINESSWIRE
VBI Vaccines Presents New Long-Term Data for 3-Antigen Adult Hepatitis B Vaccine
28 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Receives U.S. FDA ODD for VBI-1901 in Glioblastoma
22 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces Results of Annual General Meeting
22 Jun 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in the Jefferies Healthcare Conference
07 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Presents Updated PIIa Tumor Response and OS Data for VBI-1901
06 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri
01 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
26 May 2022 //
BUSINESSWIRE
VBI Vaccines Presented HEOR for PreHevbrio at ISPOR
19 May 2022 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2022 Financial Results
09 May 2022 //
BUSINESSWIRE
VBI Vaccines Announces EC Marketing Authorisation for PreHevbri
02 May 2022 //
BUSINESSWIRE
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma
28 Apr 2022 //
BUSINESSWIRE
VBI Vaccines PreHevbri Receives Approval in Europe
25 Apr 2022 //
EMA
VBI Vaccines Announces New Data and Progress of VBI-2900
05 Apr 2022 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbrio is Now Available in the U.S. for Hepatitis B
29 Mar 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
15 Mar 2022 //
BUSINESSWIRE
VBI Vaccines Reports Q4 and Full Year Financial Results for 2021
07 Mar 2022 //
BUSINESSWIRE
EMA expands nods for BMS, Eli Lilly, Novartis drugs
26 Feb 2022 //
FIERCEPHARMA
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine
25 Feb 2022 //
BUSINESSWIRE
